Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.32 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408376 | 0.79 | MAPT (0.35) | TDP1MAPTALDH1A1 | |
| SCHEMBL1518987 | 0.77 | ADAM17 (0.32) | TDP1MAPTALDH1A1 | |
| SCHEMBL8569950 | 0.74 | DPP4 (0.35) | AADATGOT1KYAT1KYAT3MAPT | |
| SCHEMBL1741998 | 0.72 | — | — | |
| SCHEMBL7203585 | 0.72 | BRD4 (0.32) | — | |
| SCHEMBL9118111 | 0.72 | APEX1 (0.31) | APEX1BLM | |
| SCHEMBL1175741 | 0.72 | AADAT (0.30) | AADAT | |
| SCHEMBL5061804 | 0.72 | BRD4 (0.33) | — | |
| SCHEMBL7851784 | 0.72 | POLB (0.34) | ALDH1A1 | |
| SCHEMBL7916866 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | APEX1 3783/4885BLM 3803/4885AADAT 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.